tiprankstipranks

Ascentage Pharma Unveils Promising Data on Alrizomadlin at ASCO 2025

Story Highlights
Ascentage Pharma Unveils Promising Data on Alrizomadlin at ASCO 2025

Don’t Miss TipRanks’ Half-Year Sale

Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has issued an update.

On June 2, 2025, Ascentage Pharma presented promising clinical data at the ASCO 2025 Annual Meeting, highlighting the potential of alrizomadlin, an MDM2-p53 inhibitor, in treating advanced adenoid cystic carcinoma (ACC) and other solid tumors. The data demonstrated significant antitumor activity, with alrizomadlin showing favorable results both as a monotherapy and in combination with the PD-1 inhibitor toripalimab. The studies underscored the therapeutic potential of alrizomadlin, suggesting it could offer new treatment strategies for patients with ACC and other challenging cancers. These developments could enhance Ascentage Pharma’s position in the oncology sector and provide new hope for patients with limited treatment options.

The most recent analyst rating on (AAPG) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Spark’s Take on AAPG Stock

According to Spark, TipRanks’ AI Analyst, AAPG is a Neutral.

The overall score is primarily driven by financial performance challenges, including negative profitability and high leverage, which pose significant risks. Technical indicators show mixed signals with some positive momentum, but valuation metrics highlight ongoing financial losses. The absence of earnings call insights and corporate events does not provide additional context for improvement.

To see Spark’s full report on AAPG stock, click here.

More about Ascentage Pharma Group International Unsponsored ADR

Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancer treatment. The company specializes in developing innovative drug candidates targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, and next-generation kinase inhibitors. Its lead assets include olverembatinib, a third-generation BCR-ABL1 inhibitor, and lisaftoclax, a Bcl-2 inhibitor, both of which are undergoing various clinical trials.

Average Trading Volume: 30,781

Current Market Cap: $2.16B

Find detailed analytics on AAPG stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1